Trial Profile
A trial to evaluate ZD1839 (IRESSA) [gefitinib] in combination with radiotherapy and gemcitabine as first-line treatment in patients with locally advanced pancreatic cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 24 Oct 2006
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 24 Oct 2006 Status change
- 23 Oct 2005 New trial record.